Lazard Asset Management LLC Buys 94,514 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Lazard Asset Management LLC grew its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 122.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 171,694 shares of the company's stock after acquiring an additional 94,514 shares during the period. Lazard Asset Management LLC owned 0.14% of Organogenesis worth $549,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of ORGO. Virtu Financial LLC acquired a new stake in shares of Organogenesis in the fourth quarter valued at approximately $38,000. Palumbo Wealth Management LLC acquired a new stake in shares of Organogenesis in the 4th quarter valued at $65,000. Algert Global LLC bought a new stake in shares of Organogenesis during the fourth quarter worth $69,000. PDT Partners LLC acquired a new position in shares of Organogenesis during the fourth quarter valued at $110,000. Finally, Aquatic Capital Management LLC acquired a new position in shares of Organogenesis during the fourth quarter valued at $111,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Morgan Stanley boosted their price objective on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th.

Insider Activity

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now directly owns 166,879 shares in the company, valued at approximately $851,082.90. This trade represents a 13.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 36.90% of the stock is owned by company insiders.

Organogenesis Trading Down 0.2%

NASDAQ ORGO traded down $0.01 during trading hours on Tuesday, hitting $2.90. The company's stock had a trading volume of 167,426 shares, compared to its average volume of 1,171,825. The stock has a fifty day moving average of $4.17 and a 200 day moving average of $3.92. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a twelve month low of $2.28 and a twelve month high of $6.71. The firm has a market capitalization of $367.24 million, a P/E ratio of -48.08 and a beta of 1.85.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $86.69 million for the quarter, compared to analyst estimates of $90.77 million. Equities research analysts forecast that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.